胰臟癌治療和診斷藥物市場（按類型和地區）

Pancreatic Cancer Therapeutics and Diagnostic Market, By Type (Treatment (Targeted Therapies, Chemotherapy, Surgery, and Other Treatments)), By Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)

出版日期: 2025年06月09日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

胰臟癌治療和診斷市場規模預計在 2025 年為 36.896 億美元，預計到 2032 年將達到 60.393 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 7.3%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	36.896億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年	7.30%	2032年價值預測	60.393億美元

胰臟癌是一種發生在胰臟細胞的癌症。當胰臟細胞發生變化（突變）導致其不受控制地生長時，就會發生胰臟癌。癌症可以透過超音波、電腦斷層掃描 (CT)、磁振造影(MRI) 或正子斷層掃描 (PET) 進行診斷。治療可能包括手術、放射線治療、化療或多種療法的組合。

市場動態

胰臟癌發病率和盛行率的上升、新型治療方法的不斷發展、老年人口的增加、對安全有效治療的需求的增加以及人們意識的提高是預計將促進全球胰臟癌治療和診斷市場成長的關鍵因素。

例如，2021年1月，Myriad Genetics Inc.和Illumina Inc.共同開發了基於套件的myChoice伴隨診斷測試版本，用於檢測胰腺癌，面向國際市場。

此外，2020年9月，印度醫學研究理事會（ICMR）-國家癌症預防和研究中心（NICPR）推出了www.cancerindia.org，這是一個門戶網站，提供有關印度主要癌症的資訊，主要關注對癌症（包括胰腺癌）的認知、預防和治療，主題為“印度抗擊癌症”。

研究的主要特點

本報告對全球胰臟癌治療和診斷市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率(CAGR)。
它強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
該報告涵蓋了全球胰腺癌藥物和診斷市場的主要企業概況，基於以下參數，例如公司亮點、產品系列、關鍵亮點、績效和策略。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
可以透過全球胰臟癌治療和診斷市場分析中使用的各種策略矩陣來促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 3,689.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.30%	2032 Value Projection:	USD 6,039.3 Mn

Pancreatic cancer is cancer that forms in the cells of the pancreas. Pancreatic cancer occurs when changes (mutations) in the pancreas cells lead them to multiply out of control. The cancer can be diagnosed with the help of ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Treatment may include surgery, radiation, chemotherapy, or a combination of these.

Market Dynamics:

Rise in incidence and prevalence of pancreatic cancer, rise in development of novel therapeutics, growing geriatric population, increase in demand for safe and effective therapeutics, and increase in awareness among people are major factors expected to augment growth of the global pancreatic cancer therapeutics and diagnostic market.

For instance, in January 2021, Myriad Genetics Inc. and Illumina Inc. collaborated to develop a kit-based version of the myChoice companion diagnostic test for international markets, which can be used to detect pancreatic cancer.

Moreover, in September 2020, the Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research (NICPR) launched www.cancerindia.org with the theme 'India against Cancer, a portal that provides information on the leading cancers in India with the major focus on awareness, prevention, and treatment of cancers, including pancreatic cancer.

Key features of the study:

This report provides in-depth analysis of the global pancreatic cancer therapeutics and diagnostic market, and provides market size (USD Million) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global pancreatic cancer therapeutics and diagnostic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include F Hoffmann-La Roche AG, Merck KgaA, Apexigen Inc., Immunovia AB, Viatris Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb, Novartis AG, Pfizer Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, FUJIFILM Holdings Corporation, Boston Scientific Corporation, and Rafael Holdings Inc. (Rafael Pharmaceuticals), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global pancreatic cancer therapeutics and diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pancreatic cancer therapeutics and diagnostic market.

Detailed Segmentation:

Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Type:
- Treatment
- Diagnostics
Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Geography:
- North America
- Europe
- Asia Pacific
- Middle East
- Africa
- Latin America
Company Profiles:
- F.Hoffmann-La Roche AG
- Merck KgaA
- Apexigen Inc.
- Immunovia AB
- Viatris Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb
- Novartis AG
- Pfizer Inc.
- Myriad Genetics Inc.
- Canon Medical Systems Corporation
- FUJIFILM Holdings Corporation
- Boston Scientific Corporation
- Rafael Holdings Inc. (Rafael Pharmaceuticals)

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rise in incidence and prevalence of pancreatic cancer
- High cost associated with diagnosis and treatments
- Increase in demand for safe and effective therapeutics
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

5. Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Geography, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
  - GCC Country
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
  - South Africa
  - North Africa
  - Central Africa

6. Competitive Landscape

F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck KgaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apexigen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Immunovia AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Myriad Genetics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
Strategies
- Canon Medical Systems Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
FUJIFILM Holdings Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boston Scientific Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Rafael Holdings Inc. (Rafael Pharmaceuticals)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views